Hérnia Lombar Gigante de Grynfelt: Relato de Caso / Grynfelt's Giant Lumbar Hernia: Case Report

Hérnia lombar é definida como a extrusão de órgãos intra ou extraperitoneais através da descontinuidade da parede abdominal posterolateral. Corresponde a menos de 1% a 2% de todas as hérnias da parede abdominal, sendo poucos os casos descritos na literatura. Quando a hérnia ocorre no triângulo de Grynfelt, ela é definida como hérnia lombar superior. Uma vez que são incomuns na prática médica, podem ser confundidas com lipomas ou mesmo abscessos. Este artigo apresenta o caso de hérnia gigante de Grynfelt em um paciente do sexo masculino, submetido ao atendimento hospitalar inicial devido à dor lombar associada à massa palpável. Descoberto o diagnóstico, foi realizada incisão transversa no ápice da hérnia onde foi identificado o saco herniário e o trígono de Grynfelt. O reparo foi realizado por meio da colocação de uma tela de polipropileno com resultados satisfatórios. Reforça-se a importância do diagnóstico de uma afecção rara e a experiência do cirurgião para uma abordagem adequada.

Safety and immunogenicity of a glycoprotein E gene-deleted bovine herpesvirus 1 strain as a candidate vaccine strain / Atenuação e imunogenicidade de uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E

A glycoprotein E-deleted Brazilian bovine herpesvirus 1 (BoHV-1gEΔ) was tested regarding to safety and immunogenicity. Intramuscular inoculation of young calves with a high virus dose did not result in clinical signs or virus shedding during acute infection or after dexamethasone administration. Calves vaccinated once IM (group I) or subcutaneously (group II) with live BoHV-1gEΔ or twice with inactivated virus plus aluminum hydroxide (group IV) or Montanide™ (group V) developed VN titers of 2 to 8 (GMT:2); 2 to 4 (GMT:1.65); 2 to 16 (GMT:2.45) and 2 to 128 (GMT:3.9), respectively. All BoHV-1gEΔ vaccinated calves remained negative in an anti-gE ELISA. Lastly, six young calves vaccinated with live BoHV-1gEΔ and subsequently challenged with a virulent BoHV-1 strain shed less virus and developed only mild and transient nasal signs comparing to unvaccinated calves. Thus, the recombinant BoHV-1gEΔ is safe and immunogenic for calves and allows for serological differentiation by a gE-ELISA test.(AU)

Um isolado brasileiro de herpesvírus bovino tipo 1, contendo uma deleção na glicoproteína E (gE - BoHV-1gEΔ) foi submetido a testes para avaliar a sua segurança e imunogenicidade em bovinos. Bezerros foram submetidos à inoculação intramuscular com uma alta dose viral e não demonstraram sinais clínicos ou excreção viral durante a fase aguda ou após tentativa de reativação viral pela administração de dexametasona. Bezerros que receberam uma dose do vírus vivo, contendo a deleção na gE, pela via intramuscular (grupo I) ou pela via subcutânea (grupo II) ou duas doses do vírus inativado utilizando o adjuvante hidróxido de alumínio (grupo IV) ou Montanide™ (grupo V), desenvolveram títulos de anticorpos neutralizantes de 2 a 8 (GMT: 2); 2 a 4 (GMT: 1,65); 2 a 16 (GMT: 2,25) e de 2 a 128 (GMT: 3,9), respectivamente. Todos os bezerros vacinados se mantiveram soronegativos quando utilizado um kit ELISA específico para a gE. Para o teste de segurança, seis bezerros foram vacinados com o vírus vivo BoHV-1gEΔ, sendo estes posteriormente desafiados com uma cepa virulenta de BoHV-1. Estes bezerros excretaram menos vírus e desenvolveram apenas sinais clínicos moderados e transitórios quando comparados com dados coletados de quatro animais não-vacinados. Com base nestes resultados, podemos confirmar que o vírus do BoHV-1 que contém a deleção na gE (BoHV-1gEΔ) é seguro e suficientemente imunogênico para bezerros e permite a diferenciação sorológica entre os animais vacinados e infectados perante a a um teste ELISA commercial específico para a gE.(AU)

Resposta sorológica aos herpesvirus bovino tipos 1 e 5 e vírus da diarreia viral bovina induzida por vacinas comerciais / Serological response to bovine herpesvírus 1 and 5 and bovine viral diarrea virus induced by comercial vaccines

Este trabalho avaliou a imunogenicidade de vacinas para os herpesvírus bovino 1 e 5 (BoHV-1, BoHV-5) e vírus da diarreia viral bovina 1 e 2 (BVDV-1, BVDV-2), disponíveis no mercado brasileiro. Para isso, novilhos de raças de corte foram alocados em grupos de 10-12 animais e vacinados duas vezes, com intervalo de 30 dias, com cada uma das oito vacinas disponíveis. Amostras de soro coletadas 30 dias após a segunda dose foram submetidas ao teste de virusneutralização (VNT), frente a cepas de BoHV-1, BoHV-5, BVDV-1 e BVDV-2. Com exceção de duas vacinas que induziram soroconversão em 8/10 e 9/10 dos animais, as demais induziram anticorpos neutralizantes contra o BoHV-1 em todos os animais vacinados (títulos médios geométricos [GMTs] entre 1,7 e 4,8). Quatro vacina s induziram anticorpos reagentes com o BoHV-5 em todos os animais (GMTs de 1,0 a 4,2), enquanto três vacinas induziram soroconversão parcial em 5/10, 6/10 e 7/10 animais. Apenas uma vacina induziu resposta sorológica detectável frente ao BVDV-1 em todos os animais vacinados (GMT=6,7). Soroconversão parcial ao BVDV-1 foi detectada em quatro grupos vacinais (6/10, GMT 4,0 6/10, GMT 5,6 e 4/10, GMT 1,8). Uma vacina induziu resposta em apenas um animal (título de 40) e três vacinas não induziram anticorpos detectáveis contra o BVDV-1 em nenhum animal. Atividade neutralizante frente ao BVDV-2 foi detectada apenas em três grupos vacinais, e parcialmente (10/10, GMT 6,5; 5/10, GMT 1,6 e 2/10, GMT 1,0). Cinco vacinas não induziram atividade neutralizante detectável frente ao BVDV-2 em nenhum dos animais imunizados. Esses resultados demonstram que o componente BoHV-1 da maioria das vacinas comerciais possui imunogenicidade adequada. No entanto, o componente BVDV da grande maioria das vacinas não induz resposta neutralizante consistente frente ao BVDV-1 e, ...

This study evaluated the immunogenicity of vaccines for bovine herpesvirus 1 and 5 (BoHV-1/5) and viral diarrhea virus 1 and 2 (BVDV-1/2) available in the Brazilian market. Calves were divided into groups (10-12), vaccinated twice with a 30 days interval. Samples collected 30 days after the second dose were submitted to virus neutralization test against BoHV-1, BoHV-5, BVDV-1 and BVDV-2. With the exception of two vaccines that induced seroconversion in 8/10 and 9/10 of the animals, the other induced antibodies against BoHV-1 in all vaccinated animals (geometric mean titers [GMTs] 1.7 and 4.8) and four induced antibodies against BoHV-5 in all animals (GMTs 1.0 to 4.2), whereas three vaccines induced partial seroconversion (5/10, 6/10 and 7/10 animals). Only one vaccine induced antibody response to BVDV-1 in all vaccinated animals (GMT=6.7). Partial seroconversion to BVDV-1 was detected in four vaccine (6/10, GMT 4.0; 6/10, GMT 5.6 and 4/10, GMT 1.8). A vaccine induced response in only one animal and three vaccines did not induce antibodies against BVDV-1 in any animal. Antibodies to BVDV-2 were detected only in three vaccine groups, and partly (10/10, GMT 6.5; 5/10, GMT 1.6 and 2/10, GMT 1.0). Five vaccines did not induce antibodies to BVDV-2 in any of the animals. Results demonstrate that the BoHV-1 component of commercial vaccines seems to have acceptable immunogenicity. However, the BVDV component of most vaccines does not induce consistent response against BVDV-1, especially, to BVDV-2. It is evident that strategies for production of vaccines, particularly to BVDV must be urgently revised.

Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine.

Foot-and-mouth disease virus (FMDV) causes a highly contagious disease of cloven-hoofed animals. We have previously demonstrated that a replication-defective human adenovirus 5 vector carrying the FMDV capsid coding region of serotype A24 Cruzeiro (Ad5-CI-A24-2B) protects swine and cattle against FMDV challenge by 7 days post-vaccination. However, since relatively large amounts of Ad5-CI-A24-2B are required to induce protection this strategy could be costly for livestock production. Poly ICLC is a synthetic double stranded RNA that activates multiple innate and adaptive immune pathways. In this study, we have tested for the first time, the adjuvant effect of poly ICLC in combination with Ad5-CI-A24-2B in swine. We found that the combination resulted in a reduction of the vaccine protective dose by 80-fold. Interestingly, the lowest dose of Ad5-CI-A24-2B plus 1mg of poly ICLC protected animals against challenge even in the absence of detectable FMDV-specific neutralizing antibodies at the time of challenge.

Type III interferon protects swine against foot-and-mouth disease.

In recent years, we have developed novel strategies to control foot-and-mouth disease (FMD), including the use of biotherapeutics such as interferons (IFN) delivered by a replication-defective human adenovirus type 5 (Ad5). Swine can be sterilely protected after vaccination with an Ad5 that encodes porcine type I IFN (poIFN-α), and cattle can be similarly protected or develop significantly reduced disease when treated with an Ad5 delivering bovine type III IFN (boIFN-λ3). Here, we have evaluated the efficacy of porcine IFN-λ3 (poIFN-λ3) against FMD virus in vivo. Swine inoculated with different doses of Ad5-poIFN-λ3 were protected against disease in a dose-dependent manner. Despite the absence of systemic antiviral activity, 7 out of 10 Ad5-poIFN-λ3 inoculated animals did not develop disease or viremia, and the other 3 inoculated animals displayed delayed and milder disease by 7 days postchallenge as compared with control animals inoculated with an Ad5 control vector. While analysis of gene expression showed significant induction of IFN and IFN-stimulated genes in Ad5-poIFN-λ3-treated cultured porcine epithelial kidney cells, there was limited gene induction in peripheral blood monocytes isolated from treated swine. These results suggest that treatment with Ad5-poIFN-λ3 is an effective biotherapeutic strategy against FMD in swine.

Intussuscepção colônica em adulto: relato de caso / Adult colonic intussusception: a case report

Intussuscepção é a penetração de um segmento do tubo gastrintestinal (TGI) em direção ao segmento adjacente. É rara em adultos e de diagnóstico difícil. Possui na faixa etária adulta, em geral, um fator precipitante. Este trabalho relata paciente adulta que se apresentou à emergência cirúrgica com abdome agudo. Realizada laparotomia de emergência que evidenciou invaginação colônica. A patologia confirmou tratar-se de lipoma como cabeça do intussuscepto.

Intussusception is the penetration of a digestive tract segment into an adjacent segment. It is rare in adults and difficult to diagnose. For adults it generally involves a precipitating factor. This paper describes an adult patient who entered the emergency department with acute surgical abdomen. Emergency laparotomy revealed colonic intussusception. The pathology confirmed a lipoma as the head of this intussusceptum.

Genetic diversity of 3' region of glycoprotein D gene of bovine herpesvirus 1 and 5.

Bovine herpesviruses 1 (BoHV-1) and 5 (BoHV-5) are closely related alphaherpesviruses of cattle. While BoHV-1 is mainly associated with respiratory/genital disease and rarely associated with neurological disease, BoHV-5 is the primary agent of meningoencephalitis in cattle. The envelope glycoprotein D of alphaherpesviruses (BoHV-1/gD1 and BoHV-5/gD5) is involved in the early steps of virus infection and may influence virus tropism and neuropathogenesis. This study performed a sequence analysis of the 3' region of gD gene (gD3') of BoHV-1 isolates recovered from respiratory/genital disease (n = 6 and reference strain Cooper) or from neurological disease (n = 7); and from seven typical neurological BoHV-5 isolates. After PCR amplification, nucleotide (nt) sequencing, and aminoacid (aa) sequence prediction; gD3' sequences were compared, identity levels were calculated, and selective pressure was analyzed. The phylogenetic reconstruction based on nt and aa sequences allowed for a clear differentiation of BoHV-1 (n = 14) and BoHV-5 (n = 7) clusters. The seven BoHV-1 isolates from neurological disease are grouped within the BoHV-1 branch. A consistent alignment of 346 nt revealed a high similarity within each viral species (gD1 = 98.3 % nt and aa; gD5 = 97.8 % nt and 85.8 % aa) and an expected lower similarity between gD1 and gD5 (73.7 and 64.1 %, nt and aa, respectively). The analysis of molecular evolution revealed an average negative selection at gD3'. Thus, the phylogeny and similarity levels allowed for differentiation of BoHV-1 and BoHV-5 species, but not further division in subspecies. Sequence analysis did not allow for the identification of genetic differences in gD3' potentially associated with the respective clinical/pathological phenotypes, yet revealed a lower level of gD3' conservation than previously reported.

Venezuelan equine encephalitis replicon particles can induce rapid protection against foot-and-mouth disease virus.

We have previously shown that delivery of the porcine type I interferon gene (poIFN-α/ß) with a replication-defective human adenovirus vector (adenovirus 5 [Ad5]) can sterilely protect swine challenged with foot-and-mouth disease virus (FMDV) 1 day later. However, the need of relatively high doses of Ad5 limits the applicability of such a control strategy in the livestock industry. Venezuelan equine encephalitis virus (VEE) empty replicon particles (VRPs) can induce rapid protection of mice against either homologous or, in some cases, heterologous virus challenge. As an alternative approach to induce rapid protection against FMDV, we have examined the ability of VRPs containing either the gene for green fluorescent protein (VRP-GFP) or poIFN-α (VRP-poIFN-α) to block FMDV replication in vitro and in vivo. Pretreatment of swine or bovine cell lines with either VRP significantly inhibited subsequent infection with FMDV as early as 6 h after treatment and for at least 120 h posttreatment. Furthermore, mice pretreated with either 10(7) or 10(8) infectious units of VRP-GFP and challenged with a lethal dose of FMDV 24 h later were protected from death. Protection was induced as early as 6 h after treatment and lasted for at least 48 h and correlated with induction of an antiviral response and production of IFN-α. By 6 h after treatment several genes were upregulated, and the number of genes and the level of induction increased at 24 h. Finally, we demonstrated that the chemokine IP-10, which is induced by IFN-α and VRP-GFP, is directly involved in protection against FMDV.

A thymidine kinase-deleted bovine herpesvirus 5 establishes latent infection but reactivates poorly in a sheep model / Recombinante do herpesvírus bovino tipo 5 com deleção na timidina quinase estabelece infecção latente porém reativa ineficientemente em ovinos

The ability of thymidine kinase (tk)-deleted recombinant bovine herpesvirus 5 (BoHV-5tkΔ) to establish and reactivate latent infection was investigated in lambs. During acute infection, the recombinant virus replicated moderately in the nasal mucosa, yet to lower titers than the parental strain. At day 40 post-infection (pi), latent viral DNA was detected in trigeminal ganglia (TG) of all lambs in both groups. However, the amount of recombinant viral DNA in TGs was lower (9.7-fold less) than that of the parental virus as determined by quantitative real time PCR. Thus, tk deletion had no apparent effect on the frequency of latent infection but reduced colonization of TG. Upon dexamethasone (Dx) administration at day 40 pi, lambs inoculated with parental virus shed infectious virus in nasal secretions, contrasting with lack of infectivity in secretions of lambs inoculated with the recombinant virus. Nevertheless, some nasal swabs from the recombinant virus group were positive for viral DNA by PCR, indicating low levels of reactivation. Thus, BoHV-5 TK activity is not required for establishment of latency, but seems critical for efficient virus reactivation upon Dx treatment.

A capacidade de um recombinante do herpesvírus bovino tipo 5 com deleção no gene da timidina quinase (BoHV-5tk∆) em estabelecer e reativar infecção latente foi investigada em cordeiros. Durante a infecção aguda, o vírus recombinante replicou na mucosa nasal em títulos moderados, porém menores do que os da cepa parental. Aos 40 dias pós-infecção (pi) DNA viral latente foi detectado no gânglio trigêmeo (TG) de todos os cordeiros em ambos os grupos. No entanto, a quantidade de DNA do vírus recombinante nos TGs foi 9,7 vezes menor do que do vírus parental, segundo determinação por PCR em tempo real. Assim, a deleção do gene tk (timidina quinase) não produziu efeito aparente sobre a frequência da infecção latente, porém reduziu a colonização do TG. Após a administração de dexametasona (Dx) no dia 40pi, os cordeiros inoculados com o vírus parental excretaram partículas virais infecciosas, contrastando com a falta de infectividade nas secreções nasais dos animais inoculados com o vírus recombinante. Entretanto, alguns suabes nasais dos cordeiros do grupo do vírus recombinante foram positivos para o DNA viral por PCR, indicando baixos níveis de reativação. Assim, a atividade da enzima timidina quinase não é requerida para o estabelecimento de latência pelo BoHV-5, mas parece fundamental para reativação eficiente da infecção latente após tratamento com Dx.

Novel antiviral therapeutics to control foot-and-mouth disease.

Foot-and-mouth disease virus (FMDV) causes a highly contagious disease of cloven-hoofed animals. Vaccines require ∼7 days to induce protection; thus, before this time, vaccinated animals are still susceptible to the disease. Our group has previously shown that swine inoculated with 1×10(11) focus forming units (FFU) of a replication-defective human adenovirus containing the gene for porcine interferon alpha (Adt-pIFN-α) are sterilely protected from FMDV serotypes A24, O1 Manisa, or Asia 1 when the animals are challenged 1 day postadministration, and protection can last for 3-5 days. Polyriboinosinic-polyribocytidylic acid stabilized with poly-l-lysine and carboxymethyl cellulose (poly ICLC) is a synthetic double-stranded RNA that is a viral mimic and activates multiple innate immune pathways through interaction with toll-like receptor 3 and MDA-5. It is a potent inducer of IFNs. In this study, we initially examined the effect of poly IC and IFN-α on FMDV replication and gene induction in cell culture. Poly ICLC alone or combined with Adt-pIFN-α was then evaluated for its therapeutic efficacy in swine against intradermal challenge with FMDV A24, 1 day post-treatment. Groups of swine were subcutaneously inoculated either with poly ICLC alone (4 or 8 mg) or in combination with different doses of Adt-pIFN-α (2.5×10(9), 1×10(9), or 2.5×10(8) FFU). While different degrees of protection were achieved in all the treated animals, a dose of 8 mg of poly ICLC alone or combined with 1×10(9) FFU of Adt-pIFN-α was sufficient to sterilely protect swine when challenged 24 h later with FMDV A24. IFN-stimulated gene (ISG) expression in peripheral blood mononuclear cells at 1 day post-treatment was broader and higher in protected animals than in nonprotected animals. These data indicate that poly ICLC is a potent stimulator of IFN and ISGs in swine and at an adequate dose is sufficient to induce complete protection against FMD.

Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle.

Interferons (IFNs) are the first line of defense against viral infections. Although type I and II IFNs have proven effective to inhibit foot-and-mouth disease virus (FMDV) replication in swine, a similar approach had only limited efficacy in cattle. Recently, a new family of IFNs, type III IFN or IFN-λ, has been identified in human, mouse, chicken, and swine. We have identified bovine IFN-λ3 (boIFN-λ3), also known as interleukin 28B (IL-28B), and demonstrated that expression of this molecule using a recombinant replication-defective human adenovirus type 5 (Ad5) vector, Ad5-boIFN-λ3, exhibited antiviral activity against FMDV in bovine cell culture. Furthermore, inoculation of cattle with Ad5-boIFN-λ3 induced systemic antiviral activity and upregulation of IFN-stimulated gene expression in the upper respiratory airways and skin. In the present study, we demonstrated that disease could be delayed for at least 6 days when cattle were inoculated with Ad5-boIFN-λ3 and challenged 24 h later by intradermolingual inoculation with FMDV. Furthermore, the delay in the appearance of disease was significantly prolonged when treated cattle were challenged by aerosolization of FMDV, using a method that resembles the natural route of infection. No clinical signs of FMD, viremia, or viral shedding in nasal swabs was found in the Ad5-boIFN-λ3-treated animals for at least 9 days postchallenge. Our results indicate that boIFN-λ3 plays a critical role in the innate immune response of cattle against FMDV. To this end, this work represents the most successful biotherapeutic strategy so far tested to control FMDV in cattle.

Inoculation of swine with foot-and-mouth disease SAP-mutant virus induces early protection against disease.

Foot-and-mouth disease virus (FMDV) leader proteinase (L(pro)) cleaves itself from the viral polyprotein and cleaves the translation initiation factor eIF4G. As a result, host cell translation is inhibited, affecting the host innate immune response. We have demonstrated that L(pro) is also associated with degradation of nuclear factor κB (NF-κB), a process that requires L(pro) nuclear localization. Additionally, we reported that disruption of a conserved protein domain within the L(pro) coding sequence, SAP mutation, prevented L(pro) nuclear retention and degradation of NF-κB, resulting in in vitro attenuation. Here we report that inoculation of swine with this SAP-mutant virus does not cause clinical signs of disease, viremia, or virus shedding even when inoculated at doses 100-fold higher than those required to cause disease with wild-type (WT) virus. Remarkably, SAP-mutant virus-inoculated animals developed a strong neutralizing antibody response and were completely protected against challenge with WT FMDV as early as 2 days postinoculation and for at least 21 days postinoculation. Early protection correlated with a distinct pattern in the serum levels of proinflammatory cytokines in comparison to the levels detected in animals inoculated with WT FMDV that developed disease. In addition, animals inoculated with the FMDV SAP mutant displayed a memory T cell response that resembled infection with WT virus. Our results suggest that L(pro) plays a pivotal role in modulating several pathways of the immune response. Furthermore, manipulation of the L(pro) coding region may serve as a viable strategy to derive live attenuated strains with potential for development as effective vaccines against foot-and-mouth disease.

Antiviral activity of bovine type III interferon against foot-and-mouth disease virus.

Foot-and-mouth disease (FMD) is one of the most serious threats to the livestock industry. Despite the availability of a vaccine, recent outbreaks in disease-free countries have demonstrated that development of novel FMD control strategies is imperative. Here we report the identification and characterization of bovine (bo) interferon lambda 3 (IFN-λ3), a member of the type III IFN family. Expression of boIFN-λ3 using a replication-defective human adenovirus type 5 vector (Ad5-boIFN-λ3) yielded a glycosylated secreted protein with antiviral activity against FMD virus (FMDV) and vesicular stomatitis virus in bovine cell culture. Inoculation of cattle with Ad5-boIFN-λ3 induced systemic antiviral activity and up-regulation of IFN stimulated gene expression in multiple tissues susceptible to FMDV infection. Our results demonstrate that the type III IFN family is conserved in bovines and boIFN-λ3 has potential for further development as a biotherapeutic candidate to inhibit FMDV or other viruses in cattle.

Atividade de três drogas antivirais sobre os herpesvírus bovino tipos 1, 2 e 5 em cultivo celular / Activity of three antiviral drugs against bovine herpesviruses 1, 2 and 5 in cell culture

The activity of three anti-herpetic drugs (Acyclovir [ACV], Gancyclovir [GCV] and Foscarnet [PFA]) was tested against bovine herpesvirus 1 (BoHV-1), 2 (BoHV-2) and 5 (BoHV-5) in vitro using the plaque reduction assay. Different drug concentrations were tested against one hundred 50 percent tissue culture infectious dose (TCID50) of the respective viruses. Drug concentrations lower than 200μg/mL resulted in viability rates of more than 80 percent for MDBK and Hep2 cells in the MTT test (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). The selectivity index (IS) of the drugs was calculated dividing the concentration of the drug that is cytotoxic for 50 percent of the cells (CC50) by the concentration of the drug that was effective in reducing by 50 percent the number of viral plaques (EC50) for the three herpesviruses. Thus, ACV was shown to be moderately active against BoHV-1 (EC50: 112.9μg/mL; IS: 4.5), BoHV-2 (EC50: 114.2μg/mL; IS: 4.5) and BoHV-5 (EC50: 96.9μg/mL; IS: 5.3). GCV was effective against BoHV-2 (EC50: 33.5μg/mL; IS: 16.6), moderately effective against BoHV-5 (EC50: 123.2μg/mL; IS: 4.5) and poorly active against BoHV-1 (EC50: 335.8μg/mL; IS: 1.7). PFA exhibited the highest antiviral activity, being the only drug that, at concentration of 100μg/mL, completely inhibited plaque formation by all three viruses. PFA was the most effective in vitro against BoHV-1 (EC50: 29.5μg/mL; IS: 42.2), BoHV-2 (EC50: 45.2μg/mL; IS: 27.6) and BoHV-5 (EC50: 7.8μg/mL; IS: 160.6). Thus, the results indicate that PFA is a promising candidate for experimental therapeutic testing in vivo against bovine herpesviruses.

A atividade de três fármacos antivirais (Aciclovir [ACV], Ganciclovir [GCV] e Foscarnet [PFA]) foi testada in vitro frente aos herpesvírus bovino tipos 1 (BoHV-1), 2 (BoHV-2) e 5 (BoHV-5). Para isso, utilizou-se o teste de reducao de placas virais em cultivo celular, testando-se diferentes concentracoes dos farmacos frente a 100 doses infectantes para 50 por cento dos cultivos celulares (DICC50) dos respectivos virus. Pelo teste de MTT (3-(4,5-Dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide), verificou-se que concentracoes inferiores a 200ƒÊg/mL dos tres antivirais resultaram em indices de viabilidade de celulas MDBK e Hep2 superiores a 80 por cento. Com base na concentracao citotoxica para 50 por cento das celulas (CC50) e na concentracao dos farmacos efetiva para inibir em 50 por cento o numero de placas virais (EC50), calculou-se o indice de seletividade (IS) dos antivirais para os tres herpesvirus. Assim, o ACV demonstrou ser moderadamente ativo frente ao BoHV-1 (EC50: 112,9ƒÊg/mL e IS: 4,5), ao BoHV-2 (EC50: 114,2 ƒÊg/mL e IS: 4,5) e BoHV-5 (EC50: 96,9ƒÊg/mL e IS: 5,3). O GCV apresentou atividade moderada frente ao BoHV-2 (EC50: 33,5ƒÊg/mL e IS: 16,6) e, em menor grau, contra o BoHV-5 (EC50: 123,2ƒÊg/mL e IS: 4,5), sendo ineficaz frente ao BoHV-1 (EC50: 335,8ƒÊg/mL e IS: 1,7). O PFA apresentou atividade antiviral mais pronunciada, sendo o unico farmaco que, na concentracao de 100ƒÊg/mL, inibiu completamente a producao de placas pelos tres virus testados. O PFA foi o mais efetivo in vitro frente ao BoHV-1 (EC50: 29,5ƒÊg/mL e IS: 42,2), ao BoHV-2 (EC50: 45,2ƒÊg/mL e IS: 27,6) e ao BoHV-5 (EC50: 7,8ƒÊg/mL e IS: 160,6). Portanto, os resultados obtidos indicam que o PFA pode se constituir em um candidato para terapia experimental de infeccoes pelos herpesvirus de bovinos in vivo.

Efeitos do Foscarnet sobre a infecção pelos herpesvírus bovino tipos 1 e 5 em coelhos / Effects of Foscarnet on the infection by bovine herpesviruses 1 and 5 in rabbits

O efeito antiviral do Foscarnet (PFA) foi demonstrado anteriormente em células de cultivo infectadas com três herpesvírus bovino (BoHV). No presente estudo, investigaram-se os seus efeitos sobre a infecção e doença causadas pelo BoHV-1 e BoHV-5 em coelhos infectados experimentalmente. Coelhos inoculados com o BoHV-5 pela via intraconjuntival (IC) e tratados com o PFA (100mg/kg/dia) a partir do dia 1 pós-inoculação (pi) apresentaram uma redução nos títulos de vírus excretados entre os dias 2 e 6 pi em comparação com o grupo não-tratado; essa diferença foi significativa no dia 3 pi [F(9,108) = 2,23; P<0,03)]. Os coelhos inoculados com o BoHV-5 e tratados com o PFA apresentaram uma redução significativa nos índices de morbidade e mortalidade (95,4 por cento [21/22] nos controles; 50 por cento [11/22] nos tratados; [P<0,0008]). Em coelhos inoculados com o BoHV-1 pela via IC, o tratamento com o PFA resultou em redução nos títulos de vírus excretados, entre os dias 1 e 4, e 6 e 7 pi. Esses animais apresentaram um período de incubação mais curto e um curso clínico mais longo comparando-se com o grupo controle não tratado (P<0,005 e P<0,04, respectivamente). O PFA também reduziu a freqüência e severidade da doença ocular nos coelhos inoculados com o BoHV-1. Esses resultados demonstram que o PFA possui atividade frente ao BoHV-1 e BoHV-5 in vivo e são promissores para o uso desse fármaco em terapias experimentais das infecções herpéticas dos animais domésticos.

The activity of Foscarnet (PFA) against three bovine herpesviruses (BoHVs) was previously demonstrated in cell culture. Herein we evaluated the effects of PFA on the infection and disease by BoHV-1 and BoHV-5 in a rabbit model. Rabbits inoculated with BoHV-5 in the conjunctival sac (IC) and treated with PFA (100 mg/kg/day) from day 1 to 17 post-inoculation (pi) shed less virus between days 2 and 6 pi comparing to untreated controls; this difference was significant at day 3 pi [F(9,108) = 2,23; P<0.03]. The morbidity and mortality rates of rabbits inoculated with BoHV-5 IC or intranasally (IN) were also significantly reduced in PFA-treated rabbits (50 percent; 11/22) comparing to untreated controls (95.4 percent; 21/22) (P<0.0008). In rabbits inoculated IC with BoHV-1, a reduction in virus shedding was observed in PFA-treated animals between days 1 and 4 pi; 6 and 7 pi. In addition, PFA-treated rabbits presented a longer incubation period and a shorter clinical course comparing to untreated controls (P<0.005 and P<0.04, respectively). The frequency and severity of ocular signs were also reduced in the PFA-treated group. These results demonstrate that PFA is effective against BoHV-1 and BoHV-5 in vivo and open the way towards its use in experimental therapy of herpetic infections in domestic animals.

Molecular identification of bovine papillomaviruses associated with cutaneous warts in southern Brazil.

Bovine papillomaviruses (BPVs) are widespread pathogens mainly associated with benign, self-limiting, cutaneous lesions (warts). At least 8 viral types, defined by serology or nucleotide sequences of the L1 gene, have been identified to date. Different serotypes are associated with the specific type and morphology of the lesion and with particular geographical regions. This article describes the molecular identification of papillomaviruses from Brazilian cattle (n = 48) and horses (n = 1) through partial amplification and sequencing of the L1 gene. Bovine papillomavirus-1 (BPV-1) was identified in warts from 29 cattle (59%), BPV-6 from 9 cattle (18%), and BPV-2 in 8 lesions (16%). Warts of 2 cattle harbored L1 sequences of a new BPV type (BAA5), otherwise identified almost exclusively in healthy skin. The newly proposed BPV type "BR-UEL-4" was identified in a sarcoid tumor of a horse. Thus, the present report provides information on the main types of BPV involved in bovine papillomatosis in Brazil and reveals a new viral type associated with equine sarcoid, which to date has been attributed exclusively to BPV-1 and BPV-2.

Differential gene expression in bovine cells infected with wild type and leaderless foot-and-mouth disease virus.

The leader proteinase (L(pro)) of foot-and-mouth disease virus (FMDV) plays a critical role in viral pathogenesis. Molecular studies have demonstrated that L(pro) inhibits translation of host capped mRNAs and transcription of some genes involved in the innate immune response. We have used microarray technology to study the gene expression profile of bovine cells infected with wild type (WT) or leaderless FMDV. Thirty nine out of approximately 22,000 bovine genes were selectively up-regulated by 2 fold or more in leaderless versus WT virus infected cells. Most of the up-regulated genes corresponded to IFN-inducible genes, chemokines or transcription factors. Comparison of promoter sequences suggested that host factors NF-kappaB, ISGF3G and IRF1 specifically contributed to the differential expression, being NF-kappaB primarily responsible for the observed changes. Our results suggest that L(pro) plays a central role in the FMDV evasion of the innate immune response by inhibiting NF-kappaB dependent gene expression.

Genital immunization of heifers with a glycoprotein Edeleted, recombinant bovine herpesvirus 1 strain confers protection upon challenge with a virulent isolate / Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E confere proteção frente a desafio com um isolado virulento

Venereal infection of seronegative heifers and cows with bovine herpesvirus type 1.2 (BoHV-1.2) frequently results in vulvovaginitis and transient infertility. Parenteral immunization with inactivated or modified live BoHV-1 vaccines often fails in conferring protection upon genital challenge. We herein report an evaluation of the immune response and protection conferred by genital vaccination of heifers with a glycoprotein E-deleted recombinant virus (SV265gE-). A group of six seronegative heifers was vaccinated with SV265gE- (0,2mL containing 10(6.9)TCID50) in the vulva submucosa (group IV); four heifers were vaccinated intramuscularly (group IM, 1mL containing 10(7.6)TCID50) and four heifers remained as non-vaccinated controls. Heifers vaccinated IV developed mild, transient local edema and hyperemia and shed low amounts of virus for a few days after vaccination, yet a sentinel heifer maintained in close contact did not seroconvert. Attempts to reactivate the vaccine virus in two IV vaccinated heifers by intravenous administration of dexamethasone (0.5mg/kg) at day 70 pv failed since no virus shedding, recrudescence of genital signs or seroconversion were observed. At day 70 pv, all vaccinated and control heifers were challenged by genital inoculation of a highly virulent BoHV-1.2 isolate (SV56/90, 10(7.1)TCID50/animal). After challenge, virus shedding was detected in genital secretions of control animals for 8.2 days (8-9); in the IM group for 6.2 days (4-8 days) and during 5.2 days (5-6 days) in the IV group. Control non-vaccinated heifers developed moderate (2/4) or severe (2/4) vulvovaginitis lasting 9 to 13 days (x: 10.7 days). The disease was characterized by vulvar edema, vulvo-vestibular congestion, vesicles progressing to coalescence and erosions, fibrino-necrotic plaques and fibrinopurulent exudate. IM vaccinated heifers developed mild (1/3) or moderate (3/4) genital lesions, lasting 10 to 12 days (x: 10.7 days); and IV vaccinated ...

A infecção genital de novilhas ou vacas soronegativas pelo herpesvírus bovino tipo 1.2 (BoHV-1.2) pode resultar em vulvovaginite e infertilidade temporária. As vacinas atenuadas ou inativadas administradas pela via parenteral freqüentemente conferem proteção incompleta frente a desafio pela via genital. Este estudo relata uma avaliação da resposta imunológica e proteção conferida pela vacinação genital de bezerras soronegativas com uma cepa recombinante do BoHV-1 defectiva na glicoproteína E (SV265gE-). Um grupo de seis bezerras foi vacinado com a cepa SV265gE(0,2mL contendo 10(6,9)TCID50) na submucosa da vulva (grupo IV); quatro bezerras foram vacinadas pela via intramuscular (IM; dose 10(7,6)TCID50) e quatro bezerras permaneceram como controles não-vacinadas. As bezerras vacinadas pela via IV apresentaram edema e hiperemia leve e transitório na vulva e excretaram vírus em títulos baixos por alguns dias após a vacinação, porém uma bezerra soronegativa mantida em contato não soroconverteu. Administração de dexametasona pela via intravenosa no dia 70pv (0,5mg/kg) em duas bezerras vacinadas pela via IV não resultou em excreção viral, recrudescência clínica ou soroconversão. No dia 70pv, as bezerras vacinadas e as controle foram desafiadas pela inoculação genital da cepa de BoHV-1.2 altamente virulenta SV56/90 (10(7.1)TCID50/animal). Após o desafio, excreção viral nas secreções genitais das bezerras controle foi detectada por 8,2 dias (8-9); no grupo IM durante 6,2 dias (4-8 dias) e durante 5,2 dias (5-6) nas bezerras do grupo IN. As bezerras do grupo controle desenvolveram vulvovaginite moderada (2/4) a severa (2/4) que duraram entre 9 e 13 dias (x: 10,7 dias). A doença se caracterizou por edema vulvar, congestão vulvo-vestibular, formação de vesículas/pústulas que coalesceram, erosões, placas fibrino-necróticas e exsudato fibrino-purulento. As bezerras do grupo IM desenvolveram lesões genitais leves (1/3) a moderadas (3/4), com duração ...

[Internal cardiac massage in dogs: a new technique proposition for emergency pericardiotomy--ligament traction]. / Massagem cardíaca interna em cães: proposição de nova técnica para pericardiotomia de emergência--tração ligamentar.

PURPOSE: Describe a technique of emergency pericardiotomy, named as Ligament Traction (LT), to reduce the necessary time to begin the Internal Cardiac Massage. To perform the ICM an emergency toracotomy and pericardiotomy are necessary, both in remote time. The technique usually employed is the "T" pericardiotomy, whose execution depends on the apprehension of the pericardium with an Allis forceps. This apprehension is difficult and complicates the reanimation of the patient. METHODS: Twenty canine corpses were divided into two groups: Group I--"T" pericardiotomy (n=10), and Group II--the LT technique (n=10). The LT consisted on the traction of the pericardiumphrenic ligament and the section of the pericardium next to its apex. The incision was elongated with the introduction of the fingers, also allowing the positioning of the heart in the hand of the operator and the immediate beginning of the ICM. RESULTS: Group I presented an execution period of 21.79 +/- 0.88 second, and Group II of 8.58 +/- 1.38, with p<0.0001 (highly expressive). CONCLUSION: The technique of pericardiotomy by Ligament Traction concur to outliving, because it avoids a larger time of cerebral ischemia, due to the early beginning of the circulation.

Massagem cardíaca interna em cães: proposição de nova técnica para pericardiotomia de emergência tração - ligamentar / Internal cardiac massage in dogs: a new technique proposition for emergency pericardiotomy - ligament traction

OBJETIVO: Descrever uma técnica de pericardiotomia de emergência, denominada Tração Ligamentar (TL), para diminuir o tempo necessário ao início da Massagem Cardíaca Interna (MCI). Para a MCI necessita-se de toracotomia de emergência e pericardiotomia, ambas em tempo mínimo. A técnica comumente empregada corresponde a pericardiotomia em "T", cuja execução depende da apreensão do pericárdio com uma pinça de Allis. Este pinçamento é difícil, dificultando a reanimação do paciente. MÉTODOS: Utilizou-se 20 cadáveres de cães, divididos em dois grupos de animais, sendo o Grupo I - pericardiotomia em "T" (n=10) e Grupo II - técnica proposta (n=10). A técnica de TL consistiu na tração do ligamento frenicopericárdico e da secção do pericárdio próximo ao seu ápice. A incisão foi alongada pelos dedos enquanto eram nela introduzidos e permitiu, também, o correto posicionamento do coração na mão do operador, bem como o pronto início da MCI. RESULTADOS: O Grupo I apresentou tempo de execução de 21,79 ± 0,88 segundo, e o Grupo II de 8,58 ± 1,38 segundo, sendo p<0,0001, (altamente significativo). CONCLUSÃO: A técnica de pericardiotomia por TL impede um tempo maior de isquemia cerebral, por iniciar prematuramente a circulação sangüínea, contribuindo para a sobrevida.